FIVE DISCOVERY Corp is a biotechnology company that develops non-hallucinogenic neuroplastogen therapeutics designed to repair and stabilize dysfunctional neural circuits. The company serves patients suffering from neurodegenerative conditions and brain injuries, including Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
Subscribe to see FIVE DISCOVERY Corp’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
FIVE DISCOVERY Corp is a biotechnology company headquartered in Charlottesville, United States. Its most recent funding round raised $150,000 in January 2026. Xcout tracks 8 named people at FIVE DISCOVERY Corp, including Sham Dholakia (Chief Medical Officer & Head of Product).
As of 16 November 2026. Source: Xcout Intel.
2 more named people on record for FIVE DISCOVERY Corp, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $150,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of FIVE DISCOVERY Corp's closest competitors — see the full list of competitors and alternatives →
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Verge Genomics develops a proprietary AI and machine learning platform utilizing human brain data to transform neuroscience drug discovery and precision neurology. The company provides foundation models and analytical tools to pharmaceutical and biotechnology developers for target discovery, biomarker identification, and clinical trial patient stratification.
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about FIVE DISCOVERY Corp? Suggest a correction · Work at FIVE DISCOVERY Corp? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.